Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 2Other hematologic neoplasm 1CNS 1

Conditions

Neuroblastoma 101Central Nervous System Neoplasms 37Medulloblastoma 35Brain Neoplasms 33Glioblastoma 20Sarcoma 16Rhabdoid Tumor 14Glioma 13Ependymoma 12Astrocytoma 11Osteosarcoma 10Neuroectodermal Tumors, Primitive 10Recurrence 9Neoplasms 9Lymphoma 9Breast Neoplasms 9Sarcoma, Ewing 8Oligodendroglioma 8Melanoma 8Ganglioneuroblastoma 8Choroid Plexus Neoplasms 8Precursor Cell Lymphoblastic Leukemia-Lymphoma 7Ovarian Neoplasms 7Neoplasm Metastasis 7Lymphoma, Non-Hodgkin 7Leukemia, Myeloid, Acute 7Gliosarcoma 7Rhabdomyosarcoma 6Multiple Myeloma 6Wilms Tumor 5

Interventions

fludarabine 1Leukapheresis 1Cyclophosphamide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Cytokine Release Syndrome × Cyclophosphamide × CNS × Clear all
NCT02761915 2021-08-17

A Phase I Trial of Anti-GD2 T-cells (1RG-CART)

Cancer Research UK

Phase 1 Completed
17 enrolled 17 charts
CNS

Cytokine Release Syndrome, Neuroblastoma, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡